Showing results (91-100 of 106) with videos related to
Sort By:
Pageof 11
Frontiers in Physiology|March 23, 2018
Antineoplastic Drug-Induced Cardiotoxicity: A Redox PerspectiveGilda Varricchi, Pietro Ameri, Christian Cadeddu, et al.Heart Failure Reviews|July 1, 2019
Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogensChristian Cadeddu Dessalvi, Alessia Pepe, Claudia Penna, et al.American Heart Journal|August 29, 2024
Association of sex with in-hospital management and outcomes of patients with heart failure: Data from the REAL-HF registryGiuseppe D Sanna, Gian Luca Erre, Matteo Cameli, et al.International Journal of Cardiology|May 15, 2015
Cardioprotection by gene therapy: A review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of CardiologyRosalinda Madonna, Christian Cadeddu, Martino Deidda, et al.European Heart Journal. Cardiovascular Imaging|January 12, 2021
Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC)Concetta Zito, Roberta Manganaro, Maurizio Cusmà Piccione, et al.Journal of Translational Medicine|June 23, 2026
Sodium-glucose cotransporter 2 inhibitors in breast cancer patients on endocrine therapy: a targeted strategy to mitigate long-term cardiometabolic riskVincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, et al.Journal of Cardiovascular Pharmacology|September 26, 2025
Time to Combinatorial Regimens: SGLT2i and PCSK9i in High-Risk Cardio-Oncology PatientsVincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, et al.International Journal of Molecular Sciences|May 4, 2026
SGLT2 Inhibitor Dapagliflozin Attenuates Cardiomyocyte Injury and Inflammation Induced by PI3Kα-Selective Inhibitor Alpelisib and Fulvestrant Under HyperglycemiaVincenzo Quagliariello, Massimiliano Berretta, Matteo Barbato, et al.International Journal of Molecular Sciences|July 29, 2025
PCSK9 Inhibitor Inclisiran Attenuates Cardiotoxicity Induced by Sequential Anthracycline and Trastuzumab Exposure via NLRP3 and MyD88 Pathway InhibitionVincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, et al.Cancers|April 14, 2025
In the Era of Cardiovascular-Kidney-Metabolic Syndrome in Cardio-Oncology: From Pathogenesis to Prevention and TherapyVincenzo Quagliariello, Massimiliano Berretta, Irma Bisceglia, et al.Pageof 11